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Abstract
Aberrant activation of -catenin has been implicated in a variety of human diseases, including cancer. In spite
of significant progress, the regulation of active Wnt/-catenin-signaling pathways is still poorly understood. In
this study, we show that F-box protein 16 (FBXO16) is a putative tumor suppressor. It is a component of the
SCF (SKP1-Cullin1-F-box protein) complex, which targets the nuclear -catenin protein to facilitate proteasomal
degradation through the 26S proteasome. FBXO16 interacts physically with the C-terminal domain of -catenin
and promotes its lysine 48-linked polyubiquitination. In addition, it inhibits epithelial-to-mesenchymal transition
(EMT) by attenuating the level of -catenin. Therefore, depletion of FBXO16 leads to increased levels of -catenin,
which then promotes cell invasion, tumor growth, and EMT of cancer cells. Furthermore, FBXO16 and -catenin
share an inverse correlation of cellular expression in clinical breast cancer patient samples. In summary, we propose
that FBXO16 functions as a putative tumor suppressor by forming an SCFFBXO16 complex that targets nuclear
-catenin in a unique manner for ubiquitination and subsequent proteasomal degradation to prevent malignancy.
This work suggests a novel therapeutic strategy against human cancers related to aberrant -catenin activation.
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Cancer is one of the leading causes of death, and breast
cancer contributes to a majority of the mortality rate
amongwomen [1,2]. Among different subtypes of breast
cancer, triple-negative breast cancer (TNBC) is associ-
ated with poor prognosis [3].
Previous reports suggested the activation of Wnt sig-
naling in 50% of breast cancer cases, with a relatively
lower frequency of somatic mutations in Wnt signal-
ing components [4–6]. Furthermore, Wnt ligands and
receptors involved in canonical Wnt signaling are often
highly expressed in breast cancer, whereas secreted
antagonists are attenuated [7–10]. Aberrant activation
of Wnt signaling results in the nuclear accumulation
of β-catenin, which is associated with invasiveness of
breast cancer with poor outcomes [11–13]. Nuclear
β-catenin functions as a transcriptional coactivator of
the TCF/LEF complex, promoting the transcriptional
activation of many oncogenes associated with increased
growth, invasion, and cellular transformation [14–16].
β-Catenin is majorly regulated by the ubiquitin pro-
teasome system (UPS), which directs the proteolysis
through polyubiquitylation by E3 ubiquitin ligases
(E3Ls). Several reports suggest that multiple E3 ubiqui-
tin ligases are involved in the proteasomal degradation
of β-catenin [17–19].
It is well known that the proteasomal degrada-
tion of cellular proteins is mostly controlled by SCF
(SKP1-Cullin1-F-box protein) E3 ubiquitin ligases.
F-box proteins are an integral component of the SCF
complex and function as substrate receptors. Human
genome encodes 69F-box proteins; however, the func-
tion of a majority of the F-box proteins remains elusive
[20]. Notably, deregulation of F-box protein-mediated
proteasomal degradation is often associated with
malignancy [21].
Here, we decipher the function of FBXO16, an F-box
protein, in cancer. In an attempt to identify interacting
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proteins of FBXO16, we adopted a mass spectrometry
approach. We identified β-catenin as a vital cellular sub-
strate of FBXO16. Our results show that FBXO16 is a
putative tumor suppressor that suppresses the growth,
migration, invasion of cancer cells, and EMT by direct-
ing the proteasomal degradation of nuclear β-catenin.
Interestingly, the expression of FBXO16 and β-catenin
is conversely correlated in breast cancer patient samples,
with the attenuation of FBXO16 expression with can-
cer progression. Altogether, these findings might con-
tribute to developing new therapeutic targets for limiting
nuclear β-catenin-mediated malignancy.
Materials and methods
Cell culture
The human cell lines MCF10A, MCF7, MDA-MB-231;
T47D and HCT-116; and HEK293 and HEK293T were
kind gifts from Prof. Michael Green (UMass Medical
School, MA, USA). MCF7, HEK-293, and HEK-293 T
cells were cultured at 37 ∘C in DMEM (Gibco,Waltham,
MA, USA). MDA-MB-231, T47D, and HCT-116 were
maintained in RPMI-1640. MCF10A cells were grown
in DMEM-F12 (Gibco) media. All tissue culture media
were supplemented with 10% FBS/horse serum and
2 mML-glutamine and were cultured in 5%CO2 at 37
∘C
in a humidified atmosphere.
Plasmid transfection
GFP-WT-β-catenin, GFP-ΔN-β-catenin, GFP-ΔC-
β-catenin, GFP-ΔNC-β-catenin, and GFP-T41A-β-
catenin were kind gifts from Dr. Jomon Joseph,
Pune, Maharashtra, India. psPAX2 and pMD2.G were
obtained from Didier Trono (Addgene, Watertown, MA,
USA 12260, 12259). Human cDNA encoding FBXO16
was procured from Origene (Rockville, MA, USA).
The F-box deletion mutant was generated using the
primers shown in supplementary material, Table S1.
Plasmids were transfected using polyethylenimine (PEI)
as described previously [22].
Cell lysate preparation and immunoblotting
Cells were harvested, washed with PBS, and lysed
with buffer on ice for 30min [23]. Cell lysates were
centrifuged at 16 000 × g, and supernatants were
collected. Cellular fractionation was performed as
described previously [24]. Protein concentration was
measured using Bradford’s method [25]. Protein
samples were immunoblotted with the indicated anti-
bodies: those for α-tubulin (T5168) and phospho
β-catenin (T41) (C-8616) were procured from Sigma
(St. Louis, MO, USA) and for ubiquitin (sc-8017), GFP
(sc-9996), SKP1 (sc-5281), Cullin 1 (sc-17775), PARP1
(sc-7150), Cyclin D1 (sc-8396), β-Trcp (sc-390629),
Twist (sc-81417), and Snail (sc-271977) from Santa
Cruz Biotechnology, Dallas, Texas, USA and those for
β-catenin (610154) and E-cadherin (610181) were from
BD Biosciences (San Diego, CA, USA). Antibodies
to c-Myc (9402), phospho GSK3β (8566), phospho
PKCδ (9376), and K48-linked ubiquitin antibodies
(8081) were from Cell Signaling Technology (Danvers,
MA, USA); to DDK (clone OTI4C5) from Origene;
and FBXO16 (PA5-31419) was from Thermo Fisher
Scientific (Waltham, MA, USA).
Coimmunoprecipitation
Immunoprecipitation was performed using 600 μg pro-
teins and 2 μg of antibody in IP lysis buffer as described
previously [23]. Immunoprecipitates were immunoblot-
ted as described above, and 3% of protein extracts was
used as input.
Identification of FBXO16 interactomes
MCF7 cells expressing either vector or DDK-FBXO16
were grown in 5 μM MG132 for 6 h before har-
vesting. Cells were lysed, and protein extracts were
immunoprecipitated with anti-DDK antibody [23]. The
immunoprecipitates were eluted from the beads using
elution buffer (8 M urea and 0.5 M Tris–pH 7.4) and
were processed for mass spectrometry. An LC–MS
(liquid chromatography–mass spectrometry)/MS
analysis of peptide mixture was performed using
Orbitrap fusion mass spectrometer (Thermo Fisher
Scientific).
Generation of stable knockdown cells
Lentiviral shRNAs (For FBXO16, shRNA 1:
V2LHS_118578 and shRNA 2: V2LHS_118583)
were a kind gift from Prof. Michael Green (UMass
Medical School, Worcester, MA, USA). Stable knock-
down cells were generated by lentivirus transduction
as described previously [24].
Colony formation assay
A total of 5000 cells (transduced/treated) were seeded
in 35mm-diameter dishes and allowed to grow
for 12–15 days to form colonies. Cells were fixed
with 3.7% formaldehyde and stained with 0.05% crystal
violet. Plates were photographed, and representative
images are shown in Figure 6A and see supplementary
material, Figure S6A.
Soft agar assays
Soft agar assays were performed as described previ-
ously [26]. In brief, 35mm-diameter dishes were filled
with 0.6% base agar (Invitrogen, Carlsbad, CA, USA;
Cat-75 510-019) and 2× RPMI 1640 (MDA-MB-231
cells)/2× DMEM (MCF7 cells) with 20% FBS and
allowed to solidify. Thereafter, 5000 cells suspended in
0.3%of agar containing 20%FBSwere placed on the top
of the base agar. Twenty days later, cells were observed
under a microscope and photographed.
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Migration and invasion assays
Scratch wound-healing assay was performed
as described previously [27]. In brief, cells were seeded
and were allowed to grow as a confluent monolayer.
A scratch-mediated wound was made in the presence
of 5 ng/ml of actinomycin D, and the open space was
tracked continuously using a phase-contrast microscope
(Olympus IX71, Shinjuku, Tokyo, Japan).
Invasion assays were performed as described previ-
ously [28]. In brief, cells were serum-starved for 24 h,
and 50 000 cells were then suspended in 200 μl of media
containing 0.5% FBS in the upper chamber. Media
containing 10% FBS was added to the lower chamber.
After 16 h of culturing, invaded cells were fixed with
3.7% formaldehyde, stained with 0.5% crystal violet,
different fields photographed, and the number of invad-
ing cells was expressed as the average number of cells
per microscopic field.
RT-qPCR
RT-qPCR was performed using SYBRmix as described
previously [24].GAPDH was used to normalize the data.
The primers used are listed in supplementary material,
Table S2.
Ubiquitination assays
In vitro and in vivo ubiquitination assays were
performed as described previously [23]. The immuno-
precipitates (in vivo) and ubiquitylation reactionmixture
(in vitro) were resolved by SDS-PAGE and blots probed
with an ubiquitin-specific antibody (we used: His-tag,
K48-linked, and those mentioned in respective figure
captions).
Immunohistochemistry
Tissue samples were obtained from SDM College
of Medical Sciences following established proto-
cols and with Institutional Ethical Board approval.
Tissue samples were stained with H&E, and the
histological type and grade of tumors were deter-
mined. β-Catenin and FBXO16 levels in breast cancer
patients, including malignant tissue and adjacent
nonmalignant epithelium, were detected using immuno-
histochemical staining and were quantified as described
previously [24].
TOP/FOP assay
Cells were seeded in a 24-well plate. Cells were trans-
duced/transfected with the indicated plasmids for 60 or
36 h, respectively. Cells were then treated with either
EGF orWnt3a-conditionedmedium for 12 h prior to har-
vesting. Luciferase activity was measured according
to the manufacturer’s protocol (Thermo Fisher Scien-
tific, Cat. no-16176), and Renilla luciferase was used
for normalization.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assay was
performed as described previously [29]. In brief, cells
expressing vector or DDK-FBXO16 were cross-linked
with 3.7% formaldehyde for 15min, followed by
quenching with 125mM glycine. Cells were then
washed with PBS and lysed. The cell lysates were soni-
cated and then incubated overnight with anti-β-catenin
antibody at 4 ∘C. Preblocked protein A agarose beads
were incubated with lysate–antibody complex for 2 h,
followed by reversal of cross-linking using proteinase
K. DNA was extracted using a phenol–chloroform
method. qPCR was performed using indicated primers
listed in supplementary material, Table S3.
Xenograft assays
MCF7 cells (5× 106 cells/mice) stably expressing NS
and FBXO16 shRNA were injected subcutaneously in
the right flank of 5-week-old NOD-SCID mice (n= 5).
The length (L) and width (W) of tumors were measured
with a digital Vernier caliper, and tumor volume was cal-
culated using the formula: V = (L×W2)/2, withW being
smaller than L. All animal experiments were approved
by the Institutional Animal Ethics Committee of the
National Centre for Cell Science.
Statistical analysis
Each experiment was repeated at least thrice. Values are
shown as mean±SD unless otherwise mentioned.
Results
FBXO16 interacts with β-catenin
The cellular function of FBXO16 is poorly understood.
To discover its cellular function and physiological sub-
strates, we performed coimmunoprecipitation followed
by mass spectrometry to identify its interacting partners.
Results demonstrated that FBXO16 interacts with 117
cellular proteins, and β-catenin was found to be the most
represented candidate, with coverage of six unique
peptides (see supplementary material, Figure S1A and
Table S4).
Next, we performed coimmunoprecipitation experi-
ments to validate the mass spectrometry finding. As
shown in Figure 1A, GFP-β-catenin could be detected in
the DDK-FBXO16 immunoprecipitates, and conversely,
DDK-FBXO16 could be detected in the GFP-β-catenin
immunoprecipitates. Similar results were obtained at
the endogenous level (Figure 1B). Notably, the pres-
ence of cullin-1 in the FBXO16 immunoprecipitates
indicated that FBXO16 is part of an SCF complex
(Figure 1B). Likewise, we also found FBXO16 and
β-catenin interaction in an unrelated cell line HEK-293,
which was increased following the addition of pro-
teasome inhibitor MG132 (see supplementary mate-
rial, Figure S1B). We also confirmed the interaction in
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Figure 1. FBXO16 interacts with β-catenin. (A) MCF7 cells coexpressing DDK-FBXO16, either with vector control or GFP-β-catenin
for 40 h, were then incubated with 5 μM MG132 for 6 h. Whole-cell lysates were immunoprecipitated with the indicated antibodies.
Immunoprecipitates and input lysates were separated on SDS-PAGE and immunoblotted for the indicated proteins. Tubulin was used as a
loading control throughout our study (n= 3). (B) Whole-cell lysates of MCF7 cells, pretreated with 5 μM MG132 for 6 h before harvesting,
were immunoprecipitated with the indicated antibodies to pull-down endogenous proteins. IgG immunoprecipitates were used as a control.
Immunoprecipitates and input lysates were separated on SDS-PAGE and immunoblotted for the indicated proteins (n= 2). (C) Nuclear and
cytoplasmic fractions were immunoprecipitated with either anti-β-catenin antibody or IgG. Immunoprecipitates and input lysates were
separated on SDS-PAGE and immunoblotted for the indicated proteins (n= 2). Cells were grown in the presence of 5 μM MG132 for 6 h
before harvesting. (D) Whole-cell protein extracts of MCF10A, MCF7, T47D, and MDA-MB-231 cells were immunoblotted for β-catenin,
FBXO16, and tubulin (n= 3). β-actin was used as a loading control. (E) (Top) Expression levels of β-catenin (top row) and FBXO16 (bottom) in
samples of normal and different grades of breast cancer. Tissues were immunostained as described in the ‘Materials and methods’ section.
Lower panel: the statistical analysis of the average score of β-catenin and FBXO16 staining between cancer tissues and corresponding
nontumor tissues, p< 0.0001 (one-way ANOVA). Staining intensity of these proteins in neoplastic cells was graded on a scale of 0 (no
staining) to 3+ (strong staining). The protein expression was scored based on the percentage of positive cells: 0= 0% of stained positive
cells; 1=weakly stained tissue or 1–25% of positive cells; 2=moderate stained tissue or 26–50% of positive stained cells; and 3= strongly
stained tissue or more than 50% of stained cells. (F) Kaplan–Meier plot depicting overall survival of breast cancer patient cohorts with
different levels of FBXO16 expression. Red trace represents comparative higher expressions of FBXO16.
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019; 248: 266–279
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vitro using purified His-FBXO16 and GST-β-catenin
(see supplementary material, Figure S1C). Subcellu-
lar localization results demonstrated that FBXO16 pre-
dominantly localizes (Figure 1C and see supplementary
material, Figure S1D) and interacts with β-catenin in the
nucleus (Figure 1C). Results taken together confirmed
that β-catenin is an interacting partner of FBXO16.
β-Catenin is known to be involved in progression and
metastasis of breast cancer, and we were intrigued to
draw up a correlation between β-catenin and FBXO16
in the context of breast cancer. Accordingly, using
different breast cell lines, we discovered an inverse
relationship between β-catenin and FBXO16 levels
(Figure 1D). For a clinical perspective, we then checked
the correlation of FBXO16 and β-catenin expression
in the breast cancer patient samples. Immunohisto-
chemical analysis demonstrated a significant converse
correlation of FBXO16 and β-catenin expression with
increased levels of β-catenin and concomitant atten-
uation of FBXO16 in higher grades of breast cancer
patient samples (Figure 1E). Interestingly, a similar
relationship was also observed irrespective of hormonal
status of breast cancer patients (see supplementary
material, Figure S1E). The attenuation of FBXO16
was further supported by the Oncomine database (see
supplementary material, Figure S1F). Furthermore,
the TCGA database demonstrated a close associa-
tion of higher FBXO16 expression with disease-free
survival (Figure 1F and see supplementary material,
Figure S1G). Collectively, our findings suggested that
FBXO16 might function as a putative tumor suppressor
by limiting nuclear β-catenin activity.
FBXO16 promotes ubiquitylation and proteasomal
degradation of β-catenin
Being an F-box family member, we presumed that
FBXO16 might regulate the stability of β-catenin at the
posttranslational level, and to test that, we performed
a series of experiments. First, the dose-dependent
ectopic expression of FBXO16 in MDA-MB-231 cells
decreased β-catenin levels (Figure 2A). Corroborating
with our finding of FBXO16’s nuclear localiza-
tion, we found a significant attenuation of nuclear
β-catenin following ectopic expression of FBXO16
(Figure 2B, supplementary material, Figure S2A).
However, RT-qPCR results suggested that CTNNB1
mRNA levels were unaffected by ectopic expression
of FBXO16 (see supplementary material, Figure S2B).
Furthermore, FBXO16-mediated reduction of β-catenin
was significantly blocked in the presence of MG132,
indicating that β-catenin stability is indeed regulated at
the posttranslational level by FBXO16 through the 26S
proteasome (Figure 2C). In addition, a cycloheximide
chase assay demonstrated that the turnover of β-catenin
was increased on FBXO16 expression (Figure 2D,
supplementary material, Figure S2C).
To demonstrate FBXO16’s ubiquitin-conjugating
action irrefutably, polyubiquitylated levels of β-catenin
were examined. An in vitro polyubiquitination assay
demonstrated that FBXO16 promotes polyubiquityla-
tion of β-catenin (Figure 2E). Furthermore, Figure 2F
shows the presence of a notable high mass ladder
of ubiquitylated β-catenin exclusively in the nuclear
fraction, suggesting that FBXO16 facilitates protea-
somal degradation of nuclear β-catenin. In addition,
Figure 2G and supplementary material, Figure S2D,
show that polyubiquitin chains on β-catenin are lysine
48 (K48)-linked, which substantiates thewidely asserted
principle that K48-based polyubiquitylation on substrate
leads to 26S proteasome-mediated degradation.
FBXO16 directs β-catenin degradation through an
SCF complex
Typically, F-box proteins associate with SKP1 to form
an SCF complex through their F-box motif and bring
their substrates to the complex for ubiquitylation. To
examinewhether FBXO16 complies with this, wild-type
and F-box-deleted FBXO16 (ΔF-FBXO16) were over-
expressed in MDA-MB-231 cells. Results demonstrated
that ΔF-FBXO16 is incompetent to reduce the expres-
sion of β-catenin (Figure 3A). Figure 3B explicitly illus-
trates that ΔF-FBXO16 did interact with its substrate,
but not with SKP1, to form the fully functional SCF
complex. This observation was further supported by
polyubiquitylation assay (see supplementary material,
Figure S3A). Interestingly, we identified the presence
of a potential nuclear localization signal (NLS) at the
C-terminus of FBXO16 (247–273 aa). Immunoblot-
ting results demonstrated that an NLS-deleted mutant
(DDK-ΔNLS-FBXO16)was predominantly localized in
the cytoplasm (see supplementarymaterial, Figure S1D)
and could not degrade nuclear β-catenin (see supplemen-
tary material, Figure S3B), suggesting that the NLS of
FBXO16 is important for nuclear β-catenin degradation.
FBXO16-mediated β-catenin degradation is
independent of its activating signals
Wnt ligands are the canonical activators of β-catenin
[30,31] and thus encouraged us to investigate whether
Wnt3a stimulation averts FBXO16-facilitated degrada-
tion of β-catenin. We performed T-cell factor/β-catenin
transcription assays (TOP/FOP assay) to assess the
transactivation of β-catenin, which demonstrated that
FBXO16-mediated β-catenin’s degradation occurs even
under Wnt3a induction (Figure 3C and supplemen-
tary material, Figure S3C). Furthermore, ectopically
expressed FBXO16 degraded the nuclear pool of
β-catenin even in presence of Wnt3a stimulation
(Figure 3D). Similar results were also obtained in the
constitutively Wnt-activated colon cancer cell line
HCT116 (see supplementary material, Figure S3D).
A previous study showed that EGF also activates
β-catenin signaling [10]. Interestingly, FBXO16 inhib-
ited β-catenin transactivation, even upon EGF stimu-
lation (Figure 3E), which is supported by TOP/FOP
assay (Figure 3F). Moreover, transcriptional activation
by ectopically expressed β-catenin was significantly
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019; 248: 266–279
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Figure 2. FBXO16 promotes proteasomal degradation of β-catenin. (A) Ectopically expressed DDK-FBXO16 decreased the levels of β-catenin
in a dose-dependent manner. Whole-cell lysates of MDA-MB-231 cells expressing either vector control or increasing doses of DDK-FBXO16
were immunoblotted with the indicated antibodies (n= 3). MDA-MB-231 cells were transfected using Lipofectamine 3000 according to
the manufacturer’s protocol throughout our study. (B) Fractionated cell lysates of MDA-MB-231 cells expressing either vector control or
DDK-FBXO16 were immunoblotted using the indicated antibodies. PARP1 and tubulin were used as nuclear and cytoplasmic loading controls,
respectively (n= 3). (C) MDA-MB-231 cells were transfected with either vector control or DDK-FBXO16 for 42 h. FBXO16-transfected cells
were then incubated with or without 5 μM MG132 for 6 h. Whole-cell lysates were immunoblotted for the indicated proteins (n= 4).
(D) Levels of β-catenin (in cycloheximide assay, see supplementary material, Figure S2C) were quantified and normalized to the loading
control. Expression levels of β-catenin were then normalized to 100% at time 0 h. (E) In vitro ubiquitylation assay showed that FBXO16
promotes ubiquitylation of β-catenin. Purified FBXO16, GST- β-catenin, ubiquitin, and E1, E2 enzymes were incubated together and
immunoblotted for anti-GST antibody. (F) Cytoplasmic (C) and nuclear (N) protein extracts of MDA-MB-231 cells expressing either vector
control or DDK-FBXO16 were immunoprecipitated with β-catenin. Immunoprecipitates and input protein extracts were immunoblotted for
indicated proteins. Cells were treated with MG132 (10 μM for 4 h) prior to lysis. PARP1 and tubulin were used as nuclear and cytoplasmic
loading controls, respectively (n= 2). (G) FBXO16 promotes K48-linked polyubiquitylation of β-catenin. Whole-cell lysates of MCF7 cells
coexpressing GFP-β-catenin and DD-FBXO16 along with HIS-K63/HIS-K48 Ub for 48 h were immunoprecipitated with anti-GFP antibody,
followed by immunoblotting for His. Whole-cell lysates were immunoblotted for the indicated proteins. The experiment was repeated three
times.
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019; 248: 266–279
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
272 D Paul et al
Figure 3. SCFFBXO16-mediated proteasomal degradation of β-catenin is independent of Wnt/EGF signaling. (A) Whole-cell protein extracts
of MDA-MB-231 cells expressing either vector control or DDK-FBXO16 or DDK-ΔF-FBXO16 for 48 h were immunoblotted for the indicated
proteins (n= 3). (B) MDA-MB-231 cells were coexpressing GFP-β-catenin either with DDK-FBXO16 or DDK-ΔF-FBXO16 for 36 h. Transfected
cells were then grown in the presence of 5 μM MG132 for 6 h. Whole-cell lysates were immunoprecipitated with anti-DDK antibody.
Immunoprecipitates and input protein extracts were resolved in SDS-PAGE and immunoblotted for the indicated proteins (n= 3). (C)
MDA-MB-231 cells were transfected with the indicated plasmids, including TOP/FOP and pRL-TK. Transfection efficiency was normalized
using the pRL-TK reporter. Luciferase activity was measured at 48 h posttransfection. After 36 h of transfection, cells were treated with
Wnt3a for 12 h. Luciferase activity is shown as a ratio of TOP and FOP. ‘ns’ means statistically not significant (n= 3). (D) Nuclear extracts
of MDA-MB-231 cells expressing either vector control or DDK-FBXO16 for 48 h were immunoblotted for the indicated proteins. At 36 h
posttransfection, cells were treated with Wnt3a for 12 h (n= 4). (E) Whole-cell lysates of MDA-MB-231 cells expressing either vector
control or DDK-FBXO16 in the absence and presence of EGF for the indicated time periods were immunoblotted for the indicated proteins.
(F) MDA-MB-231 cells were transfected with the indicated plasmids, including TOP/FOP and pRL-TK. At 36 h posttransfection, cells were
treated with EGF for 12 h, (n= 3). Luciferase activity was measured at 48 h posttransfection, and transfection efficiency was normalized
using the pRL-TK reporter. Luciferase activity is shown as a ratio of TOP and FOP (n= 3).
reduced on the coexpression of FBXO16 (see sup-
plementary material, Figure S3E). Thus, collectively,
our results suggest that FBXO16-mediated degrada-
tion of nuclear β-catenin is not overridden by upstream
Wnt/EGF signaling.
These data advocate that FBXO16 promotes
the degradation of nuclear β-catenin to ablate its
transactivation activity. However, as a final confirmatory
experiment to make our inference irrefutable, we carried
out ChIP assays with β-catenin after overexpressing
FBXO16 in MDA-MB-231 cells. Results showed that
FBXO16 abated the recruitment of β-catenin on the
promoter of its target genes, such as MYC and CCND1
(see supplementary material, Figure S3F).
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019; 248: 266–279
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
FBXO16 promotes proteasomal degradation of nuclear 𝛃-catenin 273
FBXO16 maintains physiological levels of β-catenin
Our findings suggested that ectopically expressed
FBXO16 directs the proteasomal degradation
of β-catenin. Next, we questioned whether FBXO16
maintains the basal level of β-catenin. Depletion
of FBXO16 in MCF7 cells using two unrelated shRNAs
resulted in increased β-catenin levels (Figure 4A), with
no apparent change at mRNA levels (see supplementary
material, Figure S4A). Likewise, we observed similar
findings in unrelated HEK-293 cells (see supplementary
material, Figure S4B). Furthermore, the expression of
β-catenin target genes CCND1 and MYC was signifi-
cantly elevated in FBXO16-depleted cells (Figure 4A)
at the transcript level (see supplementary material,
Figure S4A). Consistent with these findings, the ChIP
assay demonstrated that depletion of FBXO16 resulted
in increased β-catenin recruitment on the promoters of
CCND1 and MYC genes (see supplementary material,
Figure S4C).
FBXO16 depletion selectively increased nuclear
β-catenin levels (Figure 4B). Furthermore, cyclo-
heximide chase data showed that the half-life of
β-catenin was increased in FBXO16 knockdown cells
compared to the NS cells (Figure 4C, supplemen-
tary material, Figure S4D). To examine whether the
depletion of FBXO16 attenuated the polyubiquitina-
tion of β-catenin, we examined K48-linked ubiquitin
levels and found a drastic decrease in polyubiquiti-
nated β-catenin upon FBXO16 depletion (Figure 4D).
Collectively, these results suggest that FBXO16 main-
tains the basal levels of nuclear β-catenin at the
proteasomal level.
FBXO16-mediated degradation of β-catenin is
independent of GSK3β, PKCδ, and βTrCP
Typically, F-box proteins recognize phosphorylated
substrates as a mark for promoting their ubiquitylation
[32]. It is paradigmatic that GSK3β-imparted phos-
phorylation on threonine 41 of β-catenin conduces
its proteasomal degradation [33]. So, we questioned
whether FBXO16-mediated β-catenin degradation is
GSK3β dependent. Results demonstrated that, despite
administering GSK3β inhibitor BIO, FBXO16 degraded
β-catenin (see supplementary material, Figure S4E).
To further substantiate this observation, we ectopically
coexpressed the T41A mutant of GFP-β-catenin and
FBXO16 in MCF7 and found that FBXO16 degraded
the phosphorylation-defective mutant of β-catenin
equivalently to wild type (Figure 4E), indicating
that GSK3β-mediated β-catenin phosphorylation is
not required for its recognition and degradation by
FBXO16.
A recent study showed that PKCδ also plays an
important role in β-catenin degradation [19]. Hence,
we checked PKCδ’s role in this aspect and found
that FBXO16-mediated β-catenin degradation was
independent of PKCδ (see supplementary material,
Figure S4F). Moreover, we found that the interaction
between β-catenin and FBXO16 was phosphorylation-
independent (see supplementary material, Figure S4G).
We found that FBXO16 interacts physically with
β-catenin (Figure 1B). To identify the specific domain of
β-catenin that interacts with FBXO16, we used a series
of β-catenin deletion mutants (see supplementary mate-
rial, Figure S4H). Results demonstrated that FBXO16
failed to degrade C-terminal-deleted β-catenin (see sup-
plementary material, Figure S4I). Next, we checked the
interaction and found that FBXO16 does not interact
with the C-terminal deletion mutant (Figure 4F), indi-
cating that the C-terminal region of β-catenin is indis-
pensable for recognition by FBXO16.
βTrCP was the first discovered F-box protein to
degrade β-catenin [17]. Hence, we asked whether
FBXO16-mediated degradation of β-catenin was
βTrCP dependent. Immunoblotting data showed that
ectopically expressed FBXO16 degraded β-catenin
equally in both NS- and βTrCP-depleted MCF7 cells
(Figure 4G). Collectively, our results demonstrated
that FBXO16-mediated β-catenin degradation might be
independent of GSK3β, PKCδ, and βTrCP.
FBXO16 inhibits EMT by regulating β-catenin levels
β-Catenin is an exemplary regulator of EMT in develop-
ment and diseases [34]. Our results convincingly demon-
strated that FBXO16 promotes degradation of nuclear
β-catenin and vetoes upstream controller Wnt signaling
as well. This cellular interplay stoked us into assess-
ing the expression of EMT hallmarks in the presence of
FBXO16.
Ectopic expression of FBXO16 in MDA-MB-231
cells leads to the downregulation of mesenchymal mark-
ers like Snail and Twist, with concomitant upregulation
of epithelial markers like E-cadherin (Figure 5A). In
contrast, silencing FBXO16 in MCF7 cells resulted
in mesenchymal morphology (see supplementary
material, Figure S5A) and increased the expression
of EMT regulators (Figure 5B), which was restored
using the β-catenin-TCF/LEF binding inhibitor, PNU.
Another replica was performed using β-catenin shRNA
as a substitute of PNU (see supplementary material,
Figure S5B) to consolidate the finding that FBXO16
prevents β-catenin-mediated EMT. As EMT is a key
process of metastasis [35], we looked into migra-
tory potential and invasiveness of the cells following
overexpression/depletion of FBXO16. Ectopic expres-
sion of FBXO16 significantly suppressed scratch
wound healing compared to the vector-transfected
cells (Figure 5C,D), and the converse was found for
FBXO16-depleted cells (Figure 5E,F). Furthermore, the
addition of PNU suppressed the migratory potential of
FBXO16 depleted cells, suggesting that elevated levels
of β-catenin in FBXO16-depleted cells are responsible
for enhanced cell migration (Figure 5E,F). Similar
results were also observed following codepletion of
FBXO16 and β-catenin (see supplementary material,
Figure S5C,D).
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Figure 4. FBXO16 maintains the cellular level of β-catenin independent of GSK3β and βTrCP. (A) Whole-cell lysates of MCF7 cells expressing
either NS or FBXO16 shRNAs were immunoblotted for the indicated proteins (n= 4). (B) Cytoplasmic (C) and nuclear (N) extracts of MCF7
cells stably expressing NS and FBXO16 shRNA were immunoblotted for indicated proteins. PARP1 and tubulin were used as nuclear and
cytoplasmic loading controls, respectively (n= 3). Right panel shows the quantification of relative levels of β-catenin of left panel. Levels
were normalized with respect to the loading control. (C) Levels of β-catenin (in the cycloheximide assay, see supplementary material,
Figure S4D) were quantified and normalized with loading control. Expression levels of β-catenin were then normalized to 100% at time
0 h. (D) Whole-cell protein extracts of MCF7 cells stably expressing either NS or FBXO16 shRNA were immunoprecipitated using an
anti-β-catenin antibody. Immunoprecipitates and input lysates were immunoblotted for the indicated proteins (n= 3). (E) Whole-cell
lysates of MCF7 cells, coexpressing either GFP-β-catenin and vector or GFP-β-catenin and DDK-FBXO16 or GFP-T41A-β-catenin and
vector or GFP-T41A-β-catenin and DDK-FBXO16, were immunoblotted for the indicated proteins (n= 5). (F) Whole-cell protein extracts
of cells coexpressing the indicated proteins were immunoprecipitated with anti-DDK antibody. Immunoprecipitates and input lysates were
immunoblotted for the indicated proteins (n= 2). At 40 h posttransfection, cells were incubated with 5 μM MG132 for 6 h and harvested
for cell lysate preparation. (G) MCF7 cells stably expressing either NS or βTrCP shRNA were transfected with either vector control or
DDK-FBXO16 for 48 h. Whole-cell protein extracts were immunoblotted for the indicated proteins (n= 3).
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Figure 5. FBXO16 prevents EMT by limiting the expression of EMT regulators through proteasomal degradation of β-catenin. (A) Whole-cell
lysates of MDA-MB-231 cells expressing either vector control or DDK-FBXO16 were immunoblotted for the indicated proteins (n= 3). (B)
Whole-cell protein extracts of MCF7 cells stably expressing either NS or FBXO16 shRNA were immunoblotted for the indicated proteins
(n= 3). Cells were grown in the absence or presence of 500 nM PNU (β-catenin inhibitor) for 36 h. (C) Scratch wound-healing cell migration
assay of MDA-MB-231 cells expressing either vector control or FBXO16. Cells were transfected for 48 h; then, wounds were created, and
healing was tracked for 36 h (n= 3). (D) Quantitative data of scratch wound healing of three independent experiments. Wound healing
with vector was normalized to 100%. Data are presented as mean± SD. (E) Scratch would healing of MCF7 cells expressing either NS
or FBXO16 shRNA for 30 h in the absence or presence of 500 nM PNU (n= 3). (F) Quantitative data of scratch wound healing of three
independent experiments. Wound healing of NS was normalized to 100%. Data are presented as mean± SD. (G) Invasion of MDA-MB-231
cells expressing either vector control or DDK-FBXO16 (n= 3). (H) Invasion of MCF7 cells expressing either NS or FBXO16 shRNA in the
absence or presence of 500 nM PNU (n= 3).
In addition, we examined the invasion of
MDA-MB-231 cells following ectopic expression
of FBXO16, and our results showed that ectopically
expressed FBXO16 can potently suppress the inva-
sion of MDA-MB-231 cells (Figure 5G). Conversely,
depletion of FBXO16 in MCF7 cells led to significantly
enhanced invasion, which was robustly inhibited fol-
lowing treatment with PNU (Figure 5H). Collectively,
we found that FBXO16 restricts cell migration and
invasion by limiting the expression of β-catenin.
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FBXO16 inhibits tumorigenesis
The nuclear accumulation of β-catenin is a hallmark
of malignant progression through the activation of many
oncogenes [16,19,34]. We found that the mRNA lev-
els of crucial oncogenes, such as CCND1 and MYC,
were increased in FBXO16-depleted cells because of
increased β-catenin levels (see supplementary mate-
rial, Figure S4A). Hence, we performed a series of
experiments to check whether FBXO16 has any role
in cancer cell proliferation, either by its overexpres-
sion/depletion. Long-term (Figure 6A,B) and soft agar
(Figure 6C) colony formation assays demonstrated that
numbers of colonies were significantly attenuated upon
ectopic expression of FBXO16.
MDA-MB-231 cells are less sensitive to chemother-
apeutic agents such as doxorubicin. We therefore
examined whether FBXO16 has any effect on the sensi-
tivity to chemotherapeutic drugs. Results demonstrated
that the ectopic presence of FBXO16 leads to a signif-
icant increase in cell death upon doxorubicin treatment
(Figure 6D).
Next, we examined cancer cell line growth following
depletion of FBXO16 in MCF7 cells. Soft agar assays
demonstrated that depletion of FBXO16 resulted in
the formation of more colonies, which was notably
inhibited by PNU (Figure 6E,F). A similar result
was recapitulated following codepletion of β-catenin
in FBXO16 knockdown cells (see supplementary
material, Figure S6A–C). These encouraging obser-
vations prompted us to further check tumor growth as
xenografts in NOD-SCID mice. Our results demon-
strated that tumor growth was markedly increased
following depletion of FBXO16 (Figure 6G, supple-
mentary material, Figure S6D). Furthermore, IHC
showed significantly increased levels of β-catenin in
FBXO16-depleted mouse xenografts (see supplemen-
tary material, Figure S6E). Collectively, our findings
suggested that FBXO16 may function as a putative
tumor suppressor by limiting the activity of nuclear
β-catenin.
Discussion
F-box proteins form SCF complexes to target a wide
range of cellular proteins for their polyubiquitination
[20,32]. They are involved in cell cycle progression,
DNA damage response, and cellular signaling. There-
fore, deregulation of an F-box protein is often associated
with cancer. For instance, F-box protein FBXW7 func-
tions as a tumor suppressor by promoting proteasomal
degradation of c-Myc, Cyclin E, and Notch, whereas
SKP2 functions as an oncogene by promoting degrada-
tion of tumor suppressors and activating AKT signaling
by abrogating its proteasomal degradation [20]. So, it is
of prime importance to decipher the cellular functions
of F-box proteins for the development of novel targeted
therapeutics.
FBXO16 is located at human chromosome 8p12 [36].
However, the cellular function of FBXO16 is unknown.
Here, for the first time, we have identified cellular targets
of FBXO16 through mass spectrometry and unraveled
its cellular function. We show that FBXO16 functions
as a putative tumor suppressor by abrogating the func-
tion of nuclear β-catenin (Figure 6H). It maintains
the nuclear levels of β-catenin. Depletion of FBXO16
resulted in increased malignancy because of aberrant
nuclear accumulation of β-catenin, emphasizing that
elevated levels of FBXO16 in higher grades of breast
cancer could be therapeutically beneficial to abrogate the
β-catenin driven malignancy. It is further supported by a
database of breast cancer patient samples coupling over-
all survival of the patient with higher levels of FBXO16
(Figure 1F).
A recent study has found that aberrant nuclear accu-
mulation of β-catenin contributes to the malignancy
in 50% of breast cancer cases [5]. Aberrant nuclear
accumulation of β-catenin elevates the expression of
numerous oncogenes associated with cellular prolifer-
ation. Likewise, it also promotes EMT by increasing
the expression of transcription factors essential to
metastasis. Therefore, attenuating nuclear accumulation
of β-catenin might be a novel strategy for restricting
malignancy.
Recently, it has been suggested that TRIM33 directs
proteasomal degradation of nuclear β-catenin in a
PKCδ-dependent manner [19]. However, nuclear local-
ization of PKCδ is signal dependent [37]. Moreover,
we found that FBXO16 also facilitates proteaso-
mal degradation of nuclear β-catenin even in the
absence of PKCδ, indicating that FBXO16-mediated
β-catenin regulation could be different from that
of TRIM33.
A previous study demonstrated that F-box protein
βTrCP promotes the degradation of β-catenin in a
GSK3β-dependent manner. We found that FBXO16
facilitates the degradation of β-catenin even in the
absence of GSK3β signaling. Furthermore, βTrCP tar-
gets cytoplasmic pools of β-catenin, whereas FBXO16
targets nuclear pools of β-catenin. Moreover, βTrCP
fails to degrade β-catenin following activation of
Wnt/EGF; in contrast, FBXO16-mediated degradation
of β-catenin is independent ofWnt/EGF activation, indi-
cating that FBXO16-mediated regulation of β-catenin
might be different from βTrCP. Thus, FBXO16 is the
first F-box protein that facilitates degradation of nuclear
β-catenin, thereby inhibiting the cancer cell prolifera-
tion, migration, invasion in vitro, and tumor formation
in NOD-SCID mice.
A significant inverse relationship of FBXO16 and
β-catenin in breast cancer patient samples was observed.
A recent report indicated a deletion of 8p21.1 in breast
cancer, which is the chromosomal location of FBXO16
[38]. These findings indicate that downregulation of
FBXO16 in breast cancer might unleash the oncogenic
activity of β-catenin. Thus, the activation of FBXO16
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Figure 6. FBXO16 functions as putative tumor suppressor. (A) Long-term colony formation of MDA-MB-231 cells expressing either vector
control or DDK-FBXO16. A total of 5000 transfected cells were seeded and allowed to grow for 15 days, and then, colonies were stained
with crystal violet. The image represents one of the three biological replicates. (B) Number of colonies (from three independent experiments
of panel A) were counted using ImageJ software and normalized to 100% for vector-transfected cells. Data plotted as mean± SD. (C) Soft
agar colony formation assay of MDA-MB-231 cells expressing either vector control or DDK-FBXO16. A total of 5000 transfected cells were
seeded and allowed to grow for 21 days. Cells were then stained with crystal violet solution. Colonies were counted and normalized to
100% for vector control cells. Data are mean± SD from three independent experiments. (D) Relative fraction of sub-G0/G1 cell populations
plotted with indicated treatments. (E) Soft agar colony formation assay of MCF7 cells expressing either NS or FBXO16 shRNA in the presence
or absence of the β-catenin inhibitor 500 nM PNU. A total of 5000 cells were used for this assay (n= 3). (F) Number of colonies of soft agar
assay (as in panel E) was counted and normalized to 100% for NS cells. Data are mean± SD (n= 3). (G) NOD-SCID mouse xenograft growth
of MCF7 cells expressing either NS or FBXO16 shRNA. Five mice were used for each group. (H) Model depicting the tumor-suppressive
activity of FBXO16 through the regulation of β-catenin.
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expression could be a novel therapeutic strategy in pre-
venting cancers expressing the aberrant nuclear accumu-
lation of β-catenin.
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